

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



August 28, 2023

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
Scrip Name: SUNPHARMA

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
Scrip Code: 524715

Dear Sir / Madam,

Sub: Proceedings of 31st Annual General Meeting of Sun Pharmaceutical Industries Limited (“Company”) held on August 28, 2023 and Regularisation of Directors of the Company

1. Brief Proceedings of 31st Annual General Meeting

- a. The 31st Annual General Meeting (“AGM/ Meeting”) of the Company was held today i.e. Monday, August 28, 2023 at 03:00 p.m. IST through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”) in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India, from time to time.
- b. Dr. Pawan Goenka, being the Lead Independent Director of the Company, acted as the Chairman of the meeting and upon confirmation of requisite quorum being present, conducted the proceedings of the meeting.
- c. All the Directors of the Company participated in the AGM through Video Conferencing.
- d. Representatives from S R B C & Co. LLP, Statutory Auditors, KJB & Co LLP, Secretarial Auditors and M/s. K D & Co., Cost Auditors of the Company had participated in the AGM.
- e. As per requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Companies Act, 2013, remote e-voting facility was made available from August 24, 2023 to August 27, 2023 to the members to cast their votes on each of the resolutions as set out in the Notice of this Meeting. The said facility was also made available to the shareholders during the AGM and for 15 minutes after the conclusion of the Meeting.
- f. Mr. Chintan Goswami, Partner of KJB & Co LLP, Practicing Company Secretaries, was appointed as Scrutinizer to scrutinize the e-voting.
- g. The resolutions which were put up for voting at the 31st AGM are provided in **Annexure A**. All the resolutions set out in the Notice of the AGM, have been approved by the equity shareholders of the Company with requisite majority.
- h. Members who had registered themselves as speakers for the meeting, were invited to ask questions/ queries and the same were suitably replied to by Mr. Dilip Shanghvi, Managing Director of the Company.



- i. The Chairman requested the Scrutinizer to complete the scrutinizing process and submit the report to Mr. Anoop Deshpande, Company Secretary and Compliance Officer, being the person authorized by the Chairman, to submit the voting results along with Scrutinizer's Consolidated Report to the stock exchanges within two working days of the conclusion of the AGM.

2. Regularisation of Directors.

- a. Mr. Rolf Hoffmann (DIN: 10200311) has been appointed as an Independent Director of the Company for a term of 5 years effective from June 15, 2023.
- b. Mr. Aalok Shanghvi (DIN: 01951829) has been appointed as a Whole-time Director of the Company for a term of 5 years effective from June 1, 2023.

We request you to kindly take note of the same.

Thanking You,
Yours Faithfully,
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary & Compliance Officer
ICSI Membership No.: A23983



Annexure A

S. N.	Details of Resolution	Resolution Type
Ordinary Business:		
1.	Adoption of Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2023, and the reports of the Board of Directors and Auditors thereon.	Ordinary
2.	Adoption of the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2023 and the report of the Auditors thereon.	Ordinary
3.	Declaration of Final Dividend of Rs. 4/- per equity share, for the financial year 2022-23.	Ordinary
4.	Re-appointment of Mr. Sudhir Valia (DIN: 00005561), who retires by rotation, and being eligible, had offered himself for re-appointment as a Director.	Ordinary
Special Business:		
5.	Ratification of remuneration to M/s. K D & Co, Cost Accountants, the Cost Auditors for financial year 2023-24.	Ordinary
6.	Approval of Appointment of Mr. Rolf Hoffmann (DIN: 10200311) as an Independent Director of the Company from a term of 5 years effective from June 15, 2023 to June 14, 2028.	Special
7.	Approval of Appointment and remuneration of Mr. Aalok Shanghvi (DIN: 01951829) as the Whole-time Director of the Company for a term of 5 years effective from June 01, 2023 to May 31, 2028.	Special
8.	Approval of material related party transactions for purchase and sale of pharmaceutical products between Taro Pharmaceuticals USA, Inc and Taro Pharmaceuticals Inc., Canada, both non-wholly owned subsidiaries of the Company, for the financial year 2023-24, not exceeding an aggregate value equivalent to Rs. 20,000 Million.	Ordinary